Surv BioPharma selected for up to ¥2.7 billion in AMED support
The programme backs development of the company’s immune-gene oncolytic virus.
AMED selected Surv BioPharma’s Surv.m-CRA-2-IC programme for its Drug Discovery Venture Ecosystem initiative on 4 December 2025. In a 22 December announcement, the company put the potential support at up to approximately ¥2.7 billion over the project’s full term.
The subsidy is linked to investment by certified venture capital firms. Those firms must provide at least one-third of eligible research and development costs; AMED can provide up to twice their investment. DCI Partners is the project’s lead certified VC.
Surv BioPharma plans to advance nonclinical and clinical development of its immune-gene oncolytic virus for difficult-to-treat cancers.
Use of funds
Nonclinical and clinical development of Surv.m-CRA-2-IC